Literature DB >> 29249556

Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers.

Hai-Yun Wu1, Xue-Qi Tang1, Hao Liu1, Xiao-Fang Mao1, Yong-Xiang Wang2.   

Abstract

GLP-1 receptor agonists, exenatide and GLP-1, promoted M2 type polarization in monocytes/macrophages and microglial cells. This study explored the signal basis underlying exenatide-stimulated expression of M2 microglia-specific genes, including the cytoplasmic marker Arg 1, surface marker CD206, and secretion protein marker IL-4. Treatment with exenatide in cultured primary microglial cells concentration dependently stimulated the expression of Arg 1, CD206 and IL-4, but did not significantly alter LPS-stimulated expression of TNF-α, IL-1β and IL-6. The stimulatory effects of exenatide were completely prevented by the GLP-1 receptor antagonist exendin(9-39), but not altered by application of LPS. Furthermore, the adenylyl cyclase inhibitor DDA, PKA inhibitor H89 and CREB inhibitor KG501 completely blocked exenatide-induced overexpression of Arg 1, CD206 and IL-4. In addition, exenatide-stimulated expression of Arg 1 and CD206 was totally blocked by the p38 MAPK inhibitor SB203580 and gene silencer siRNA/p38β (but not siRNA/p38α), whereas the expressed IL-4 was not significantly altered by the p38 inhibitor or other MAPK subtype inhibitors. These findings revealed that both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β/CREB mediated GLP-1 receptor agonism-induced overexpression of M2 microglial biomarkers.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CREB; Exenatide; GLP-1 receptor; M2 microglia polarization; cAMP/PKA; p38β MAPK

Mesh:

Substances:

Year:  2017        PMID: 29249556     DOI: 10.1016/j.jneuroim.2017.12.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

1.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

2.  Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Authors:  Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Chaim G Pick; Nigel H Greig; Dong Seok Kim
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

Review 3.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

4.  Increased Retinal Ganglion Cell Survival by Exogenous IL-2 Depends on IL-10, Dopamine D1 Receptors, and Classical IL-2/IL-2R Signaling Pathways.

Authors:  Tamiris Gago Colares; Camila Saggioro de Figueiredo; Lucienne de Oliveira Jesus Souza; Aline Araujo Dos Santos; Elizabeth Giestal-de-Araujo
Journal:  Neurochem Res       Date:  2021-04-01       Impact factor: 3.996

5.  The protective effect of Palmatine on depressive like behavior by modulating microglia polarization in LPS-induced mice.

Authors:  Lei Wang; Min Li; Cuiping Zhu; Aiping Qin; Jinchun Wang; Xianni Wei
Journal:  Neurochem Res       Date:  2022-08-02       Impact factor: 4.414

Review 6.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

7.  Cynandione A Alleviates Neuropathic Pain Through α7-nAChR-Dependent IL-10/β-Endorphin Signaling Complexes.

Authors:  Qiao-Qiao Han; Min Yin; Zi-Ying Wang; Hao Liu; Jun-Ping Ao; Yong-Xiang Wang
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

8.  Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization.

Authors:  Kai Shan; Ninghan Feng; Jing Cui; Shunhe Wang; Hongyan Qu; Guoling Fu; Jiaqi Li; Heyan Chen; Xiaoying Wang; Rong Wang; Yumin Qi; Zhennan Gu; Yong Q Chen
Journal:  J Cell Mol Med       Date:  2020-05-29       Impact factor: 5.310

9.  Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.

Authors:  Seung Pil Yun; Tae-In Kam; Nikhil Panicker; SangMin Kim; Yumin Oh; Jong-Sung Park; Seung-Hwan Kwon; Yong Joo Park; Senthilkumar S Karuppagounder; Hyejin Park; Sangjune Kim; Nayeon Oh; Nayoung Alice Kim; Saebom Lee; Saurav Brahmachari; Xiaobo Mao; Jun Hee Lee; Manoj Kumar; Daniel An; Sung-Ung Kang; Yunjong Lee; Kang Choon Lee; Dong Hee Na; Donghoon Kim; Sang Hun Lee; Viktor V Roschke; Shane A Liddelow; Zoltan Mari; Ben A Barres; Valina L Dawson; Seulki Lee; Ted M Dawson; Han Seok Ko
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

10.  The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors.

Authors:  Evhy Apryani; Usman Ali; Zi-Ying Wang; Hai-Yun Wu; Xiao-Fang Mao; Khalil Ali Ahmad; Xin-Yan Li; Yong-Xiang Wang
Journal:  J Neuroinflammation       Date:  2020-02-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.